Thus, MIB/MS analysis identified MEK and IKKα as important downstream targets of Lyn, suggesting that co-targeting these kinases may provide a unique strategy to inhibit Lyn-dependent imatinib-resistant CML. This evidence concerns the gene MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive.